Lower Eyelid Blepharoplasty: Who Is a Candidate and Who Should Choose Filler

Lower eyelid blepharoplasty or filler — which one fits you?

The answer depends on what is actually wrong under your eye, not on which option is less invasive. If your lower eyelid fat has pushed forward and formed a bag, filler will not flatten that bulge; the literature is explicit that when fat herniation is present, hyaluronic acid gives limited results and fat repositioning is the more logical option. If the problem is a mild-to-moderate tear trough hollow with good skin quality and no lid laxity, filler is a reasonable, adjustable choice. And if your lower lid has become lax, white sclera shows below the iris, or you have malar mounds and edema, neither should be your first step — those findings need a closer examination and tend to get worse with a simple injection.

This article is written to prepare you for a consultation, not to diagnose you remotely. No text replaces an eyelid examination, an assessment of eye health, and hands-on testing of lower lid tone. But knowing what a surgeon looks at, and why, makes your decision better and makes you far harder to sell an inappropriate procedure.

Four different problems under the eye that all get called "bags" or "hollows"

Most of the confusion in this decision comes from one place: four very different conditions look alike in the mirror, but they do not share a treatment. A 2020 review in the Indian Journal of Ophthalmology describes the combination as a "double convex deformity" of the lower eyelid — an upper convexity from prolapsed orbital fat, a concavity at the bony orbital rim, and a lower convexity from the malar mound.

One — herniated lower eyelid fat

Here the orbital fat pads push forward past the septum that normally holds them back, creating a visible bulge. The classic sign is that the bulge becomes more obvious in upgaze — a simple manoeuvre that appears in the standard preoperative examination checklist. Filling around a bulge does not flatten the bulge; it may simply make the whole area look heavier.

Two — a tear trough hollow

The tear trough is the narrow groove running from the inner corner of the eye toward the cheek. Volume loss, descent of midface structures and skin thinning make it deeper and cast a shadow. The 2020 review reports the mean age of tear trough appearance as 38–51 years in Caucasian populations and 40–60 years in an Indian cohort, with early signs from age 35–40. This is the condition tear trough filler was designed for.

Three — horizontal lid laxity and loss of lower lid tone

Over time the lower lid stretches horizontally and the lateral canthal tendon loosens. If this laxity is not identified before surgery, lower blepharoplasty can lead to the lid turning outward (ectropion), lid retraction and visible scleral show. This is exactly why lateral canthopexy is now regarded as an integral part of lower eyelid blepharoplasty rather than an optional extra.

Four — malar edema, malar mounds and festoons

Puffiness sitting slightly below the lid, over the cheekbone, is not an eyelid fat bag. A 2020 systematic review in the Aesthetic Surgery Journal stresses that managing this area is complex because the underlying mechanism and severity vary widely, and that treatment must be individualised according to the extent and the "content" of the mound — fluid, fat, or lax skin. This region responds poorly to blind injection.

Who is a candidate for lower eyelid blepharoplasty?

A good candidate has a structural problem that surgery can correct, and a realistic expectation of the result. The 2020 review lists the common indications for lower eyelid blepharoplasty as: lower lid wrinkling and excess skin, relative fat prolapse, a pronounced nasojugal groove, infraorbital and malar deflation, malar mounds or festoons, and asymmetry between the two lids.

The important point is that the finding determines the type of surgery, not merely whether surgery is needed. The same review recommends working from an algorithm that weighs six things: the amount of excess skin, the degree of orbital fat herniation, hollowness at the infraorbital rim, lateral canthal laxity, lower lid tone, and the vector of the lid–cheek complex.

On that basis:

• A younger patient with fat prolapse and no excess skin is a candidate for the transconjunctival approach, done from inside the lid with no external skin incision.
• A patient with genuine excess skin needs a transcutaneous (subciliary) approach, because skin cannot be removed from inside the lid.
• A patient whose main issue is hollowing and deflation needs fat repositioned or volume added rather than fat taken away.
• A patient with horizontal lid laxity needs lateral canthal support built into the operation, or the risk of lid malposition rises.

The choice of approach has real consequences. A comparative study cited in that review reported scleral show in 3% of transconjunctival cases versus 28% of transcutaneous cases. A second point matters just as much: removing all three fat pads produces a hollowed appearance and, in some cases, lid retraction — which is why current practice favours preserving and repositioning fat rather than excising it.

The examination that should happen before this decision

The preoperative checklist for lower eyelid blepharoplasty is well defined in the specialist literature, and not one item on it can be replaced by looking at a selfie. The 2020 review names: a full medical and ophthalmic history including previous surgery, lower lid position, periocular skin quality, orbital fat prolapse (made more obvious in upgaze), the presence of a tear trough, inferior scleral show, dry eye examination, horizontal lid laxity, canthal tendon laxity, cheek projection, malar festoons, and negative vector calculation — the relationship between the bony orbital rim and the most forward point of the lid and globe.

Two of these matter most in practical terms for a patient:

Negative vector. When the globe sits forward of the bony rim and cheek, the lower lid has less skeletal support behind it. That anatomy makes the lid more vulnerable to retraction and descent after surgery and changes the operative plan. It matters for injection too, because it leaves less room to add volume without an unnatural bulge.

Pre-existing dry eye. In the largest series cited in the 2025 systematic review — 892 upper and lower blepharoplasties by a single surgeon — preoperative dry eye symptoms were a risk factor for postoperative chemosis, and preoperative scleral show was associated with a higher risk of postoperative dry eye. If you already have dry eye, it belongs in the conversation before the decision, not after it.

Who should choose filler instead?

A 2024 review in the Journal of Personalized Medicine, which examined 20 studies comparing fat repositioning with hyaluronic acid filler, offers a clear dividing line. Filler suits:

• People whose tear trough hollow is mild to moderate (Barton grade I–II, Hirmand class I–II)
• Younger patients who want a non-surgical option
• People who cannot take time off for recovery
• People with good skin quality and minimal laxity

By contrast, the same review favours fat repositioning for severe hollows (grade III) or when excess skin is present, particularly in older patients who want a durable result.

Satisfaction with tear trough filler is genuinely high. A 2024 meta-analysis in Aesthetic Plastic Surgery pooling 31 reports and 2,556 patients calculated an overall satisfaction rate of 91.0% (95% CI 84.9–95.7). The volumes involved are small: in a retrospective study of 155 patients treated between 2007 and 2023, an average of 0.45 mL was injected per hollow using a cannula.

Who should not choose filler?

This is where most dissatisfaction is created — not by a complication, but by matching the wrong method to the wrong problem.

When the main problem is herniated fat. The 2024 review states plainly that in the presence of fat pad herniation, hyaluronic acid gives limited results and fat repositioning is the better option. Filling the hollow beneath a bulge does not shrink the bulge.

When the hollow is severe or there is excess skin. Grade III hollowing and lax skin are not injection problems, and a large volume of filler in thin eyelid skin becomes a source of deformity in its own right.

When you have malar edema or festoons. A 2023 duplex ultrasound case series of 17 patients (26 eyes) who developed malar edema after periocular filler found the filler sitting inside the SMAS layer in 23 eyes, with veno-lymphatic compression as the probable mechanism; after ultrasound-guided removal, venous flow returned and the edema improved. The point patients should take from that report: onset ranged from the same day up to three years after injection, so the absence of an immediate reaction is no guarantee this will not happen.

When the real issue is pigmentation. The 2024 review notes that in patients with pigmented skin but no true hollowing, neither filler nor fat repositioning helps. Working out what is causing the darkness — pigment, shadow, or superficial vessels — has to come first.

When you have a marked negative vector and very thin skin. Thin eyelid skin increases the chance of the filler showing as a blue-grey discolouration (the Tyndall effect) and of surface irregularity.

What actually goes wrong, with numbers

Tear trough filler

The 2024 meta-analysis (31 reports, 2,556 patients) produced these pooled rates:

Most of these are mild and temporary. But there is one rare, serious complication worth understanding: vascular occlusion and visual loss. The route is anatomical — the infraorbital artery connects to the ophthalmic artery, and intravascular injection can carry filler backward to occlude the ophthalmic artery and cause blindness. In the Beleznay tally cited in the 2024 review, among 98 recorded cases of visual change after filler, the highest-risk sites were the glabella (38.8%), the nose (25.5%), the nasolabial folds (13.3%) and the forehead (12.2%); autologous fat was implicated in 47.9% and hyaluronic acid in 23.5%. That same review notes that using a cannula rather than a needle reduces the risk of vascular complications.

Lower eyelid blepharoplasty

A 2025 systematic review in Plastic and Reconstructive Surgery Global Open examined 36 studies and summarised the complication profile as follows:

The review's overall conclusion matters: no major complication resulting in ocular or visual disturbance was reported across the included studies, and the majority of functional and aesthetic complications were resolved with conservative management or revision surgery. At the same time, the authors stress that variation in study design and follow-up length made a meta-analysis — and any precise comparison between techniques — impossible.

Two commoner problems that patients are often not told about:

• Chemosis (conjunctival swelling): in the 892-patient series, the overall rate was 26.3% and 15.6% in the lower-lid-only group. Every case resolved within 180 days, with a mean of 26 days and a median of 14. Risk factors: combined upper and lower blepharoplasty, skin-muscle flap technique, male sex, preoperative lid laxity, preoperative dry eye symptoms, and canthopexy.
• Dry eye: in the same series, 26.5% reported dry eye symptoms. In a separate series of 202 patients, 10.9% had symptoms beyond two weeks and 2% beyond two months; 95.5% resolved with conservative management and 0.5% needed revision surgery.

Bruising is very common — the reported range is 20% to 96.3% depending on technique — and post-inflammatory hyperpigmentation was seen in 1.8% to 14.4% of patients, more often in higher Fitzpatrick skin types. The UK's National Health Service also expects most people to take about two weeks off work to recover, and states plainly that the result of cosmetic eyelid surgery cannot be guaranteed.

Filler versus lower eyelid blepharoplasty, side by side

The part that rarely gets said: under-eye filler is not temporary

The most common mistake in this field is the reassurance "just try filler, it'll be gone in six months anyway." Imaging evidence does not support that.

In a 2024 MRI study of 33 patients, all of whom had last had midface injections at least two years earlier, hyaluronic acid was visible on imaging in all 33 and no patient showed complete resorption. Of those, 21 had not been injected for two to five years, 12 for more than five years, four for more than eight, two for more than ten to twelve, and one for more than fifteen. The authors present this as contradicting the traditional "3 to 12 months" figure. The study is small and did not quantify the residual volume precisely, but the direction of the finding is clear.

Efficacy data point the same way: in the retrospective study of 155 patients, improvement in infraorbital hollow grading remained significant to 18 months, with no significant difference between the 6-, 12- and 18-month follow-ups.

The clinical consequence of that persistence was published in 2025 in Plastic and Reconstructive Surgery: a series of 48 patients with a history of under-eye or cheek filler who later presented for lower eyelid surgery. In that group, 35.4% had been injected more than three years earlier and 31.3% could not recall when. 83.3% showed at least one filler-associated adverse effect, hyaluronidase was frequently needed before surgery to dissolve the filler, and 43.8% experienced prolonged postoperative edema requiring further intervention and follow-up.

What this means for you in practice: treating filler as a risk-free trial run before deciding on surgery is not a sound assumption. If you think you may eventually have surgery, raise that at the very first consultation.

If you need both, what is the right order?

Many patients have a mixture: a little fat prolapse, a little hollowing, and some loss of cheek volume. Three points help here:

• Structure first, fine-tuning second. When surgery is indicated, it makes more sense to reposition or adjust the fat first and then, if a residual hollow remains, complete the result with careful volume. The reverse order means operating on tissue that already contains filler.
• Report your injection history fully. In the 2025 series, roughly a third of patients could not recall when they had last been injected. Write down the product name, the approximate date and the area treated, and give it to your surgeon; our list of questions to ask at the consultation also helps you prepare.
• Fat repositioning targets the hollow too. Current practice in lower blepharoplasty is to preserve fat and move it toward the hollow rather than remove it entirely — which means that for some patients a single operation addresses both the bulge and the groove and reduces the need for injection.

Common mistakes in this decision

• Deciding from someone else's photographs. Your result depends on your own lid laxity, skin thickness and lid–cheek vector; on the limits of those photos, see how to read before-and-after photos correctly.
• Confusing morning puffiness with a fat bag. Transient swelling that improves by midday is usually not a structural problem, and neither filler nor surgery fixes it.
• Ignoring dry eye. Preoperative dry eye symptoms are a recognised risk factor for postoperative chemosis and belong in the decision.
• Choosing a technique without accounting for excess skin. If you have excess skin, an approach that does not remove skin will not solve your problem.
• Expecting shadows to disappear completely. Part of under-eye darkness is pigmentary or vascular and is not corrected by filling or removing fat.
• Repeat injections to fix a poor result. Adding volume on top of filler that is still in the tissue raises the chance of malar edema and irregularity.

When to seek care urgently

These are emergencies and should not be waited out:

• During or immediately after a filler injection: severe pain out of proportion to the procedure, blanching or mottling of the skin, any change or loss of vision, double vision, or eye pain. These are possible signs of vascular occlusion and need immediate assessment.
• After eyelid surgery: severe, increasing eye pain with reduced vision or a bulging globe, active bleeding, or an inability to close the eyelid.
• At any point: spreading redness with fever and purulent discharge, or persistent blurred or double vision.

These are not emergencies but should be raised at a follow-up visit: swelling that persists beyond a few weeks, a palpable lump or irregularity, obvious asymmetry between the two sides, or dryness and burning that continues beyond two weeks.

If you are unsure what is going on with your own eyelids, the right route is an in-person examination. Our blepharoplasty (eyelid surgery) page explains how the procedure runs at Se Rokh, and if your question is about the price difference between upper and lower lids, the cost of upper and lower eyelid blepharoplasty covers exactly that.

Sources

• Gimenez et al., Safety and Complications in Lower Eyelid Blepharoplasty: A Systematic Review, Plastic and Reconstructive Surgery Global Open, 2025
• Christodoulou et al., Surgical and Non-Surgical Approach for Tear Trough Correction: Fat Repositioning Versus Hyaluronic Acid Fillers, Journal of Personalized Medicine, 2024
• Liu et al., The Efficacy and Safety of Hyaluronic Acid Injection in Tear Trough Deformity: A Systematic Review and Meta-analysis, Aesthetic Plastic Surgery, 2024
• Bhattacharjee et al., Lower eyelid blepharoplasty: An overview, Indian Journal of Ophthalmology, 2020
• Master et al., Hyaluronic Acid Filler Longevity in the Mid-face: A Review of 33 Magnetic Resonance Imaging Studies, Plastic and Reconstructive Surgery Global Open, 2024
• Yao et al., Navigating Lower Eyelid Blepharoplasty in Patients with Under-Eye Filler, Plastic and Reconstructive Surgery, 2025
• Puyana & Montes, Long-Term Effects of Tear Trough Hyaluronic Acid Filler: A Retrospective Study, Journal of Clinical and Aesthetic Dermatology, 2025
• Schelke et al., Periorbital venous stasis may be involved with filler induced malar edema, Journal of Cosmetic Dermatology, 2023
• Newberry et al., Updated Management of Malar Edema, Mounds, and Festoons: A Systematic Review, Aesthetic Surgery Journal, 2020
• NHS, Eyelid surgery (blepharoplasty)